pCMV-MMLVgag-3xNES-Cas9 Citations (3)
Originally described in: Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins.Banskota S, Raguram A, Suh S, Du SW, Davis JR, Choi EH, Wang X, Nielsen SC, Newby GA, Randolph PB, Osborn MJ, Musunuru K, Palczewski K, Liu DR Cell. 2022 Jan 7. pii: S0092-8674(21)01484-7. doi: 10.1016/j.cell.2021.12.021. PubMed Journal
Articles Citing pCMV-MMLVgag-3xNES-Cas9
| Articles |
|---|
Prediction of efficiencies for diverse prime editing systems in multiple cell types.
Yu G, Kim HK, Park J, Kwak H, Cheong Y, Kim D, Kim J, Kim J, Kim HH.
Cell. 2023 Apr 21:S0092-8674(23)00331-8. doi: 10.1016/j.cell.2023.03.034.
PubMed
Associated Plasmids |
| Deep Characterization and Comparison of Different Retrovirus-like Particles Preloaded with CRISPR/Cas9 RNPs. Wichmann M, Maire CL, Nuppenau N, Habiballa M, Uhde A, Kolbe K, Schroder T, Lamszus K, Fehse B, Glow D. Int J Mol Sci. 2023 Jul 13;24(14):11399. doi: 10.3390/ijms241411399. PubMed |
| An innovative approach using CRISPR-ribonucleoprotein packaged in virus-like particles to generate genetically engineered mouse models. Jeong TY, Yoon DE, Kim SP, Yang J, Lim SY, Ok S, Ju S, Park J, Lee SB, Park SJ, Kim S, Lee H, Lee D, Kang SK, Lee SE, Kim HS, Seong JK, Kim K. Nat Commun. 2025 Apr 11;16(1):3451. doi: 10.1038/s41467-025-58364-7. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.